nach oben

International Urology and Nephrology

Erschienen in:

12.07.2019 | Urology - Review

The impact of microbiome in urological diseases: a systematic review

verfasst von: Joseph K. M. Li, Peter K. F. Chiu, Chi-Fai Ng

Erschienen in: International Urology and Nephrology | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

The term microbiome is used to signify the ecological community of commensal, symbiotic, and pathogenic microorganisms that share our body space, in which there were increasing evidences to suggest that they might have potential roles in various medical conditions. While the study of microbiome in the urinary system is not as robust as the systems included in the Human Microbiome Project, there are still evidences in the literature showing that microbiome may have a role in urological diseases. Therefore, we would like to perform a systematic review on the topic and summarize the available evidence on the impact of microbiome on urological diseases.

Methodology

This review was performed according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. After screening 589 abstracts and including additional studies (such as references from review papers), 76 studies were included for review and discussion.

Results

Studies had suggested that there were correlations of microbiome of different body cavities (e.g., fecal, urinary and seminal fluid) with urological diseases. Also, different diseases would have different microbiome profile in different body cavities. Unfortunately, the studies on the association of microbiome and urological diseases were still either weak or inconsistent.

Conclusion

Studies suggested that there might be some relationship between microbiome and various urological diseases. However, further large-scale studies with control of confounding factors should be performed under a standardized methodology in order to have better understanding of the relationship. Also, more standardized reporting protocol for microbiome studies should be considered for better communications in future studies.

Savage DC (1977) Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 31(1):107–133. https://doi.org/10.1146/annurev.mi.31.100177.000543 CrossRefPubMed

Lederberg J, McCray A (2001) ’Ome Sweet’Omics—a genealogical treasury of words. Scientist 15:8

Whiteside SA, Razvi H, Dave S, Reid G, Burton JP (2015) The microbiome of the urinary tract–a role beyond infection. Nat Rev Urol 12(2):81–90. https://doi.org/10.1038/nrurol.2014.361 CrossRefPubMed

Cho I, Blaser MJ (2012) The human microbiome: at the interface of health and disease. Nat Rev Genet 13(4):260–270. https://doi.org/10.1038/nrg3182 CrossRefPubMedPubMedCentral

Ursell LK, Metcalf JL, Parfrey LW, Knight R (2012) Defining the human microbiome. Nutr Rev 70(Suppl 1):S38–S44. https://doi.org/10.1111/j.1753-4887.2012.00493.x CrossRefPubMedPubMedCentral

NIH HMP Working Group J, Peterson J, Garges S et al (2009) The NIH Human Microbiome Project. Genome Res 19(12):2317–2323. https://doi.org/10.1101/gr.096651.109 CrossRef

Nelson DE, van der Pol B, Dong Q et al (2010) Characteristic male urine microbiomes associate with asymptomatic sexually transmitted infection. PLoS One 5(11):1–7. https://doi.org/10.1371/journal.pone.0014116 CrossRef

Wolfe AJ, Toh E, Shibata N et al (2012) Evidence of uncultivated bacteria in the adult female bladder. J Clin Microbiol 50(4):1376–1383. https://doi.org/10.1128/JCM.05852-11 CrossRefPubMedPubMedCentral

Fouts DE, Pieper R, Szpakowski S et al (2012) Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury. J Transl Med 10(1):174. https://doi.org/10.1186/1479-5876-10-174 CrossRefPubMedPubMedCentral

10.

Khasriya R, Sathiananthamoorthy S, Ismail S et al (2013) Spectrum of bacterial colonization associated with urothelial cells from patients with chronic lower urinary tract symptoms. J Clin Microbiol 51(7):2054–2062. https://doi.org/10.1128/JCM.03314-12 CrossRefPubMedPubMedCentral

11.

Hilt EE, McKinley K, Pearce MM et al (2014) Urine is not sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult female bladder. J Clin Microbiol 52(3):871–876. https://doi.org/10.1128/JCM.02876-13 CrossRefPubMedPubMedCentral

12.

Pearce MM, Hilt EE, Rosenfeld AB et al (2014) The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. mBio 5(4):e01283-01214. https://doi.org/10.1128/mbio.01283-14 CrossRef

13.

Moreno CE, Rodríguez P (2010) A consistent terminology for quantifying species diversity? Oecologia 163(2):279–282. https://doi.org/10.1007/s00442-010-1591-7 CrossRefPubMed

14.

Garrett WS (2015) Cancer and the microbiota. Science 348(6230):80–86. https://doi.org/10.1126/science.aaa4972 CrossRefPubMedPubMedCentral

15.

Liss MA, White JR, Goros M et al (2018) Metabolic biosynthesis pathways identified from fecal microbiome associated with prostate cancer. Eur Urol 74(5):575–582. https://doi.org/10.1016/j.eururo.2018.06.033 CrossRefPubMedPubMedCentral

16.

Amirian ES, Petrosino JF, Ajami NJ, Liu Y, Mims MP, Scheurer ME (2013) Potential role of gastrointestinal microbiota composition in prostate cancer risk. Infect Agent Cancer 8(1):42. https://doi.org/10.1186/1750-9378-8-42 CrossRefPubMedPubMedCentral

17.

Pascale A, Marchesi N, Govoni S, Coppola A, Gazzaruso C (2019) The role of gut microbiota in obesity, diabetes mellitus, and effect of metformin: new insights into old diseases. Curr Opin Pharmacol 49:1–5. https://doi.org/10.1016/j.coph.2019.03.011 CrossRefPubMed

18.

Golombos DM, Ayangbesan A, O’Malley P et al (2018) The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. Urology 111:122–128. https://doi.org/10.1016/j.urology.2017.08.039 CrossRefPubMed

19.

Sfanos KS, Markowski MC, Peiffer LB et al (2018) Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer Prostatic Dis 21(4):539–548. https://doi.org/10.1038/s41391-018-0061-x CrossRefPubMedPubMedCentral

20.

Yow MA, Tabrizi SN, Severi G et al (2017) Characterisation of microbial communities within aggressive prostate cancer tissues. Infect Agent Cancer 12:4. https://doi.org/10.1186/s13027-016-0112-7 CrossRefPubMedPubMedCentral

21.

Cavarretta I, Ferrarese R, Cazzaniga W et al (2017) The microbiome of the prostate tumor microenvironment. Eur Urol 72(4):625–631. https://doi.org/10.1016/j.eururo.2017.03.029 CrossRefPubMed

22.

Feng Y, Ramnarine VR, Bell R et al (2019) Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer. BMC Genomics 20(1):146. https://doi.org/10.1186/s12864-019-5457-z CrossRefPubMedPubMedCentral

23.

Alanee S, El-Zawahry A, Dynda D et al (2019) A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis. Prostate 79(1):81–87. https://doi.org/10.1002/pros.23713 CrossRefPubMed

24.

Shrestha E, White JR, Yu S-H et al (2018) Profiling the urinary microbiome in men with positive versus negative biopsies for prostate cancer. J Urol 199(1):161–171. https://doi.org/10.1016/j.juro.2017.08.001 CrossRefPubMed

25.

Xu W, Yang L, Lee P et al (2014) Mini-review: perspective of the microbiome in the pathogenesis of urothelial carcinoma. Am J Clin Exp Urol 2(1):57–61PubMedPubMedCentral

26.

Popović VB, Šitum M, Chow C-ET, Chan LS, Roje B, Terzić J (2018) The urinary microbiome associated with bladder cancer. Sci Rep 8(1):12157. https://doi.org/10.1038/s41598-018-29054-w CrossRef

27.

Wu P, Zhang G, Zhao J et al (2018) Profiling the urinary microbiota in male patients with bladder cancer in China. Front Cell Infect Microbiol 8:167. https://doi.org/10.3389/fcimb.2018.00167 CrossRefPubMedPubMedCentral

28.

Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813. https://doi.org/10.1056/NEJMoa1510665 CrossRefPubMedPubMedCentral

29.

Lopez-Beltran A, Henriques V, Cimadamore A et al (2018) The identification of immunological biomarkers in kidney cancers. Front Oncol 8:456. https://doi.org/10.3389/fonc.2018.00456 CrossRefPubMedPubMedCentral

30.

Routy B, Le Chatelier E, Derosa L et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359(6371):91–97. https://doi.org/10.1126/science.aan3706 CrossRefPubMed

31.

Yi M, Qin S, Chu Q, Wu K (2018) The role of gut microbiota in immune checkpoint inhibitor therapy. Hepatobiliary Surg Nutr 7(6):481–483. https://doi.org/10.21037/hbsn.2018.11.12 CrossRefPubMedPubMedCentral

32.

Shigematsu Y, Inamura K (2018) Gut microbiome: a key player in cancer immunotherapy. Hepatobiliary Surg Nutr 7(6):479–480. https://doi.org/10.21037/hbsn.2018.10.02 CrossRefPubMedPubMedCentral

33.

Gutierrez Millet V, Praga M, Miranda B et al (1985) Ureolytic Citrobacter freundii infection of the urine as a cause of dissolution of cystine renal calculi. J Urol 133(3):443–446CrossRef

34.

Stern JM, Moazami S, Qiu Y et al (2016) Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers. Urolithiasis 44(5):399–407. https://doi.org/10.1007/s00240-016-0882-9 CrossRefPubMed

35.

Suryavanshi MV, Bhute SS, Jadhav SD, Bhatia MS, Gune RP, Shouche YS (2016) Hyperoxaluria leads to dysbiosis and drives selective enrichment of oxalate metabolizing bacterial species in recurrent kidney stone endures. Sci Rep 6:34712. https://doi.org/10.1038/srep34712 CrossRefPubMedPubMedCentral

36.

Tang R, Jiang Y, Tan A et al (2018) 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones. Urolithiasis 46(6):503–514. https://doi.org/10.1007/s00240-018-1037-y CrossRefPubMed

37.

Allison MJ, Dawson KA, Mayberry WR, Foss JG (1985) Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol 141(1):1–7CrossRef

38.

Kaufman DW, Kelly JP, Curhan GC et al (2008) Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 19(6):1197–1203. https://doi.org/10.1681/ASN.2007101058 CrossRefPubMedPubMedCentral

39.

Batagello CA, Monga M, Miller AW (2018) Calcium oxalate urolithiasis: a case of missing microbes? J Endourol 32(11):995–1005. https://doi.org/10.1089/end.2018.0294 CrossRefPubMed

40.

Lieske JC (2017) Probiotics for prevention of urinary stones. Ann Transl Med 5(2):29. https://doi.org/10.21037/atm.2016.11.86 CrossRefPubMedPubMedCentral

41.

Cai T, Mazzoli S, Mondaini N et al (2012) The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clin Infect Dis Off Publ Infect Dis Soc Am 55(6):771–777. https://doi.org/10.1093/cid/cis534 CrossRef

42.

McDonald M, Kameh D, Johnson ME, Johansen TEB, Albala D, Mouraviev V (2017) A head-to-head comparative Phase II study of standard urine culture and sensitivity versus DNA next-generation sequencing testing for urinary tract infections. Rev Urol 19(4):213–220. https://doi.org/10.3909/riu0780 CrossRefPubMedPubMedCentral

43.

Mouraviev V, McDonald M (2018) An implementation of next generation sequencing for prevention and diagnosis of urinary tract infection in urology. Can J Urol 25(3):9349–9356PubMed

44.

Darouiche RO, Green BG, Donovan WH et al (2011) Multicenter randomized controlled trial of bacterial interference for prevention of urinary tract infection in patients with neurogenic bladder. Urology. 78(2):341–346. https://doi.org/10.1016/j.urology.2011.03.062 CrossRefPubMed

45.

Darouiche RO, Thornby JI, Cerra-Stewart C, Donovan WH, Hull RA (2005) Bacterial interference for prevention of urinary tract infection: a prospective, randomized, placebo-controlled, double-blind pilot trial. Clin Infect Dis Off Publ Infect Dis Soc Am 41(10):1531–1534. https://doi.org/10.1086/497272 CrossRef

46.

Sundén F, Håkansson L, Ljunggren E, Wullt B (2010) Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J Urol 184(1):179–185. https://doi.org/10.1016/j.juro.2010.03.024 CrossRefPubMed

47.

Biehl LM, Cruz Aguilar R, Farowski F et al (2018) Fecal microbiota transplantation in a kidney transplant recipient with recurrent urinary tract infection. Infection 46(6):871–874. https://doi.org/10.1007/s15010-018-1190-9 CrossRefPubMed

48.

Wang T, Kraft CS, Woodworth MH, Dhere T, Eaton ME (2018) Fecal microbiota transplant for refractory Clostridium difficile infection interrupts 25-year history of recurrent urinary tract infections. Open Forum Infect Dis. 5(2):ofy016. https://doi.org/10.1093/ofid/ofy016 CrossRefPubMedPubMedCentral

49.

Tariq R, Pardi DS, Tosh PK, Walker RC, Razonable RR, Khanna S (2017) Fecal microbiota transplantation for recurrent Clostridium difficile infection reduces recurrent urinary tract infection frequency. Clin Infect Dis Off Publ Infect Dis Soc Am 65(10):1745–1747. https://doi.org/10.1093/cid/cix618 CrossRef

50.

Antunes-Lopes T, Vale L, Coelho AM et al (2018) The role of urinary microbiota in lower urinary tract dysfunction: a systematic review. Eur Urol Focus 1:1. https://doi.org/10.1016/j.euf.2018.09.011 CrossRef

51.

Siddiqui H, Lagesen K, Nederbragt AJ, Jeansson SL, Jakobsen KS (2012) Alterations of microbiota in urine from women with interstitial cystitis. BMC Microbiol 12:205. https://doi.org/10.1186/1471-2180-12-205 CrossRefPubMedPubMedCentral

52.

Nickel JC, Stephens-Shields AJ, Landis JR et al (2019) A culture-independent analysis of the microbiota of female interstitial cystitis/bladder pain syndrome participants in the MAPP research network. J Clin Med. https://doi.org/10.3390/jcm8030415 CrossRefPubMedPubMedCentral

53.

Abernethy MG, Rosenfeld A, White JR, Mueller MG, Lewicky-Gaupp C, Kenton K (2017) Urinary microbiome and cytokine levels in women with interstitial cystitis. Obstet Gynecol 129(3):500–506. https://doi.org/10.1097/AOG.0000000000001892 CrossRefPubMed

54.

Nickel JC, Stephens A, Landis JR et al (2016) Assessment of the lower urinary tract microbiota during symptom flare in women with urologic chronic pelvic pain syndrome: a MAPP network study. J Urol 195(2):356–362. https://doi.org/10.1016/j.juro.2015.09.075 CrossRefPubMed

55.

Braundmeier-Fleming A, Russell NT, Yang W et al (2016) Stool-based biomarkers of interstitial cystitis/bladder pain syndrome. Sci Rep 6:26083. https://doi.org/10.1038/srep26083 CrossRefPubMedPubMedCentral

56.

Ivanov IB, Kuzmin MD, Gritsenko VA (2009) Microflora of the seminal fluid of healthy men and men suffering from chronic prostatitis syndrome. Int J Androl 32(5):462–467. https://doi.org/10.1111/j.1365-2605.2008.00878.x CrossRefPubMed

57.

Mändar R, Punab M, Korrovits P et al (2017) Seminal microbiome in men with and without prostatitis. Int J Urol Off J Jpn Urol Assoc 24(3):211–216. https://doi.org/10.1111/iju.13286 CrossRef

58.

Nickel JC, Stephens A, Landis JR et al (2015) Search for microorganisms in men with urologic chronic pelvic pain syndrome: a culture-independent analysis in the MAPP research network. J Urol 194(1):127–135. https://doi.org/10.1016/j.juro.2015.01.037 CrossRefPubMedPubMedCentral

59.

Shoskes DA, Altemus J, Polackwich AS, Tucky B, Wang H, Eng C (2016) The urinary microbiome differs significantly between patients with chronic prostatitis/chronic pelvic pain syndrome and controls as well as between patients with different clinical phenotypes. Urology 92:26–32. https://doi.org/10.1016/j.urology.2016.02.043 CrossRefPubMed

60.

Magri V, Boltri M, Cai T et al (2019) Multidisciplinary approach to prostatitis. Arch Ital Urol Androl Organo Uff Soc Ital Ecogr Urol E Nefrol 90(4):227–248. https://doi.org/10.4081/aiua.2018.4.227 CrossRef

61.

Shoskes DA, Wang H, Polackwich AS, Tucky B, Altemus J, Eng C (2016) Analysis of gut microbiome reveals significant differences between men with chronic prostatitis/chronic pelvic pain syndrome and controls. J Urol 196(2):435–441. https://doi.org/10.1016/j.juro.2016.02.2959 CrossRefPubMed

62.

Mändar R, Punab M, Borovkova N et al (2015) Complementary seminovaginal microbiome in couples. Res Microbiol 166(5):440–447. https://doi.org/10.1016/j.resmic.2015.03.009 CrossRefPubMed

63.

Groah SL, Pérez-Losada M, Caldovic L et al (2016) Redefining healthy urine: a cross-sectional exploratory metagenomic study of people with and without bladder dysfunction. J Urol 196(2):579–587. https://doi.org/10.1016/j.juro.2016.01.088 CrossRefPubMed

64.

Brubaker L, Nager CW, Richter HE et al (2014) Urinary bacteria in adult women with urgency urinary incontinence. Int Urogynecol J 25(9):1179–1184. https://doi.org/10.1007/s00192-013-2325-2 CrossRefPubMedPubMedCentral

65.

Pearce MM, Zilliox MJ, Rosenfeld AB et al (2015) The female urinary microbiome in urgency urinary incontinence. Am J Obstet Gynecol 213(3):347.e1–347.e11. https://doi.org/10.1016/j.ajog.2015.07.009 CrossRef

66.

Fok CS, Gao X, Lin H et al (2018) Urinary symptoms are associated with certain urinary microbes in urogynecologic surgical patients. Int Urogynecol J 29(12):1765–1771. https://doi.org/10.1007/s00192-018-3732-1 CrossRefPubMed

67.

Thomas-White KJ, Kliethermes S, Rickey L et al (2017) Evaluation of the urinary microbiota of women with uncomplicated stress urinary incontinence. Am J Obstet Gynecol 216(1):55.e1–55.e16. https://doi.org/10.1016/j.ajog.2016.07.049 CrossRef

68.

Karstens L, Asquith M, Davin S et al (2016) Does the urinary microbiome play a role in urgency urinary incontinence and its severity? Front Cell Infect Microbiol 6:78. https://doi.org/10.3389/fcimb.2016.00078 CrossRefPubMedPubMedCentral

69.

Wu P, Chen Y, Zhao J et al (2017) Urinary microbiome and psychological factors in women with overactive bladder. Front Cell Infect Microbiol 7:488. https://doi.org/10.3389/fcimb.2017.00488 CrossRefPubMedPubMedCentral

70.

Thomas-White KJ, Hilt EE, Fok C et al (2016) Incontinence medication response relates to the female urinary microbiota. Int Urogynecol J 27(5):723–733. https://doi.org/10.1007/s00192-015-2847-x CrossRefPubMed

71.

Bajic P, Van Kuiken ME, Burge BK et al (2018) Male bladder microbiome relates to lower urinary tract symptoms. Eur Urol Focus 1:1. https://doi.org/10.1016/j.euf.2018.08.001 CrossRef

72.

Jarvi K, Lacroix JM, Jain A, Dumitru I, Heritz D, Mittelman MW (1996) Polymerase chain reaction-based detection of bacteria in semen. Fertil Steril 66(3):463–467CrossRef

73.

Kiessling AA, Desmarais BM, Yin H-Z, Loverde J, Eyre RC (2008) Detection and identification of bacterial DNA in semen. Fertil Steril 90(5):1744–1756. https://doi.org/10.1016/j.fertnstert.2007.08.083 CrossRefPubMed

74.

Hou D, Zhou X, Zhong X et al (2013) Microbiota of the seminal fluid from healthy and infertile men. Fertil Steril 100(5):1261–1269. https://doi.org/10.1016/j.fertnstert.2013.07.1991 CrossRefPubMedPubMedCentral

75.

Baud D, Pattaroni C, Vulliemoz N, Castella V, Marsland BJ, Stojanov M (2019) Sperm microbiota and its impact on semen parameters. Front Microbiol 10:234. https://doi.org/10.3389/fmicb.2019.00234 CrossRefPubMedPubMedCentral

76.

Chen H, Luo T, Chen T, Wang G (2018) Seminal bacterial composition in patients with obstructive and non-obstructive azoospermia. Exp Ther Med 15(3):2884–2890. https://doi.org/10.3892/etm.2018.5778 CrossRefPubMedPubMedCentral

77.

Alfano M, Ferrarese R, Locatelli I et al (2018) Testicular microbiome in azoospermic men-first evidence of the impact of an altered microenvironment. Hum Reprod Oxf Engl 33(7):1212–1217. https://doi.org/10.1093/humrep/dey116 CrossRef

Titel: The impact of microbiome in urological diseases: a systematic review
verfasst von: Joseph K. M. Li
Peter K. F. Chiu
Chi-Fai Ng
Publikationsdatum: 12.07.2019
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 10/2019
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-019-02225-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Nierenkarzinom | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The impact of microbiome in urological diseases: a systematic review

Abstract

Objective

Methodology

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Update Innere Medizin

Springer Medizin

Abstract

Objective

Methodology

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2019

Intravesical application of platelet-rich plasma in patients with persistent haemorrhagic cystitis after hematopoietic stem cell transplantation: a single-centre preliminary experience

Left ventricular end-diastolic pressure-guided hydration for the prevention of contrast-induced acute kidney injury in patients with stable ischemic heart disease: the LAKESIDE trial

The ideal position of the peritoneal dialysis catheter is not always ideal

Heart rate effects of antimuscarinic drugs

Possible clinical implications of peripheral zone changes depending on prostate size

Calcitriol and FGF-23, but neither PTH nor sclerostin, are associated with calciuria in CKD

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Update Innere Medizin